Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:08:35.433Z.
Calculation as of: 2026-10-06T19:08:35.433Z.
Quote observation: 2026-10-06T19:05:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cf9736c803d76d66c79e1885a68840785ad6b55ce886a17ac328e1a4bc30d25a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$2.11B
EV/EBITDA Ratio
12.85x
TTM Avg
13.80x
3Y Avg
16.03x
5Y Avg
17.55x
Market Cap
$2.06B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.07B
EV/EBITDA Ratio
N/A
TTM Avg
238.50x
3Y Avg
123.46x
5Y Avg
123.46x
Market Cap
$2.06B
EV/EBITDA Ratio
65.47x
TTM Avg
96.19x
3Y Avg
628.91x
5Y Avg
603.99x
Market Cap
$2.13B
EV/EBITDA Ratio
N/A
TTM Avg
156.56x
3Y Avg
157.08x
5Y Avg
157.08x
Market Cap
$2.04B
EV/EBITDA Ratio
N/A
TTM Avg
88.86x
3Y Avg
88.86x
5Y Avg
88.86x
Market Cap
$2.13B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | $2.09B | N/A | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.07B | 41.92x | 33.53x | 180.18x | 180.18x |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 12.85x | 13.80x | 16.03x | 17.55x |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | N/A | 238.50x | 123.46x | 123.46x |
| Vericel Corporation (VCEL)vs › | $2.06B | 65.47x | 96.19x | 628.91x | 603.99x |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | N/A | 156.56x | 157.08x | 157.08x |
| UroGen Pharma Ltd. (URGN)vs › | $2.04B | N/A | 88.86x | 88.86x | 88.86x |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.13B | N/A | N/A | N/A | N/A |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | N/A | 40.61x | 40.61x | 40.61x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
